Takeda Pharmaceutical Company Limited

Tokyo Stock Exchange:4502.T

Location

Market Cap

USD 47.11 B

Share Price

USD 30.16

Avg Daily Volume

5,104,727

Change (1 day)

-0.03%

Change (1 year)

16.64%

Change (YTD)

13.23%

Takeda Pharmaceutical Company Limited Current Ratio for the year ending March 31, 2025: 1.01

Takeda Pharmaceutical Company Limited Current Ratio is 1.01 for the year ending March 31, 2025, a -9.07% change year over year. Current ratio represents the short-term liquidity measurement, showing current assets' coverage of liabilities. Higher ratio implies better ability to meet short-term obligations.
  • Takeda Pharmaceutical Company Limited Current Ratio for the year ending March 31, 2024 was 1.11, a 14.49% change year over year.
  • Takeda Pharmaceutical Company Limited Current Ratio for the year ending March 31, 2023 was 0.97, a -20.07% change year over year.
  • Takeda Pharmaceutical Company Limited Current Ratio for the year ending March 31, 2022 was 1.21, a -21.00% change year over year.
  • Takeda Pharmaceutical Company Limited Current Ratio for the year ending March 31, 2021 was 1.53, a 34.81% change year over year.
Key data
Date Current Ratio Interest Coverage Ratio Return on Capital Employed (ROCE) Return on Equity (ROE)
Market news
Loading...
Tokyo Stock Exchange: 4502.T

Takeda Pharmaceutical Company Limited

CEO Mr. Christophe Weber
IPO Date Jan. 4, 2000
Location Japan
Headquarters 1-1, Nihonbashi-Honcho 2-chome
Employees 49,281
Sector 🏥 Health Care
Industries
Description

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

Similar companies

ABBV

AbbVie Inc.

USD 182.31

-2.40%

NOVO-B.CO

Novo Nordisk A/S

USD 68.56

1.71%

RO.SW

Roche Holding AG

USD 347.50

0.20%

ABT

Abbott Laboratories

USD 134.38

0.53%

NOVN.SW

Novartis AG

USD 120.31

0.29%

AZN.L

AstraZeneca PLC

USD 140.24

0.73%

MRK

Merck & Co., Inc.

USD 79.10

0.34%

AMGN

Amgen Inc.

USD 277.13

-0.71%

PFE

Pfizer Inc.

USD 24.19

-0.21%

GILD

Gilead Sciences, Inc.

USD 110.67

2.83%

SAN.PA

Sanofi

USD 96.65

0.37%

VRTX

Vertex Pharmaceuticals Incorporated

USD 441.30

-0.47%

BMY

Bristol-Myers Squibb Company

USD 46.35

-0.64%

4519.T

Chugai Pharmaceutical Co., Ltd.

USD 51.91

-1.13%

GSK.L

GSK plc

USD 19.28

0.69%

CSL.AX

CSL Limited

USD 153.01

-2.58%

MRK.DE

MERCK Kommanditgesellschaft auf Aktien

USD 131.98

1.04%

REGN

Regeneron Pharmaceuticals, Inc.

USD 521.00

0.00%

600276.SS

Jiangsu Hengrui Medicine Co., Ltd.

USD 7.24

-0.32%

ALNY

Alnylam Pharmaceuticals, Inc.

USD 322.83

1.44%

UCB.BR

UCB SA

USD 199.41

0.97%

GEHC

GE HealthCare Technologies Inc.

USD 74.38

-0.64%

BAYN.DE

Bayer AG

USD 31.61

2.81%

068270.KS

Celltrion, Inc.

USD 116.73

-0.46%

2359.HK

WuXi AppTec Co., Ltd.

USD 9.68

-1.75%

3692.HK

Hansoh Pharmaceutical Group Company Limited

USD 3.71

-0.01%

LH

Laboratory Corporation of America Holdings

USD 260.59

1.41%

INSM

Insmed Incorporated

USD 99.49

-2.21%

RPRX

Royalty Pharma plc

USD 35.87

1.70%

BIIB

Biogen Inc.

USD 126.08

-0.66%

4503.T

Astellas Pharma Inc.

USD 9.69

0.99%

1801.HK

Innovent Biologics, Inc.

USD 9.85

-1.60%

SMMT

Summit Therapeutics Inc.

USD 20.60

-3.38%

4507.T

Shionogi & Co., Ltd.

USD 17.51

-0.68%

TORNTPHARM.NS

Torrent Pharmaceuticals Limited

USD 39.09

3.96%

GMAB.CO

Genmab A/S

USD 205.20

-0.79%

NBIX

Neurocrine Biosciences, Inc.

USD 125.42

-1.02%

EXEL

Exelixis, Inc.

USD 43.67

1.35%

MANKIND.NS

Mankind Pharma Limited

USD 27.30

1.56%

603392.SS

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

USD 8.56

0.65%

RGC

Regencell Bioscience Holdings Limited

USD 17.40

-13.82%

9926.HK

Akeso, Inc.

USD 11.78

-2.48%

ASND

Ascendis Pharma A/S

USD 172.22

-0.42%

LUPIN.NS

Lupin Limited

USD 22.64

0.60%

BMRN

BioMarin Pharmaceutical Inc.

USD 55.17

1.98%

SOBI.ST

Swedish Orphan Biovitrum AB (publ)

USD 29.88

2.57%

IPN.PA

Ipsen S.A.

USD 120.09

-0.15%

000963.SZ

Huadong Medicine Co., Ltd

USD 5.63

0.53%

4151.T

Kyowa Kirin Co., Ltd.

USD 16.88

-1.46%

StockViz Staff

June 30, 2025

Any question? Send us an email